Taiwan’s Foxconn said on Wednesday it expects any impact of new tariffs from U.S. President-elect Donald Trump to hit it less ...

As (bio)pharma companies continue to focus on their core competencies they continue to rely on contract manufacturing organizations (CMOs).

Foxconn would only be able to share more details about the company's US plans after Jan 20, once Trump takes office and his ...

Outsourcing Trend in the Biopharmaceutical Industry Pharmaceutical companies are increasingly outsourcing their manufacturing processes to Contract Development and Manufacturing Organizations (CDMOs) ...

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic ...

The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it has entered into a collaboration with an undisclosed European pharmaceutical ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it unveils a $3.5 billion infusion into US sites.

At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

Trump’s second inning is likely to spell uncertainty for pharma companies, says Nandini Piramal, referring to his plan to ...